Official Title: “A Prospective, Randomized, Double-Blind, Double-Dummy, Forced Titration, Parallel Group Comparison, Multicenter Trial to Compare the Effects of Either Telmisartan (40-80 mg p.o. Once Daily) or Ramipril (5-10 mg p.o. Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 di”

The primary objective was to evaluate the effect of 9 weeks treatment with either telmisartan or ramipril on NO bioavailability in the renal vasculature, measured as renal plasma flow (RPF) in response to NG-monomethyl-L-arginine (LNMMA) infusion..

Study Type: Interventional

Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

This study was designed as a randomised, double-blind, double-dummy, parallel group in hypertensive patients with type 2 diabetes and normo- or microalbuminuria over a treatment period of 9 weeks After a 4 weeks Run-in period, patients were randomised to one of the treatment groups and receive either Telmisartan 40 - 80 mg or Ramipril 5 - 10 mg. The treatment regimen is a forced titration with the lower dose given for 3 weeks and the higher dose given for the rest of the treatment perid summing up to 9 weeks of treatment. During the treatment period, 3 visits to the investigator were scheduled in order to control blood pressure, renal function parameters and safety. In addition, parameters of endothelial function in the rebal vaculature, based on a nephrological clearance investigation and a provocation with L-NMMA were measured at baseline and after 9 weeks of treatment..

Study Hypothesis:

Due to the exploratory nature of the trial, the primary objective to evaluate the effect on RPF in response to L-NMMA infusion at baseline and after 9 weeks of therapy with either telmisartan 80 mg or ramipril 10 mg was not planned to be addressed by a test of prespecified hypotheses..

Comparison(s):

The change in RPF from baseline (Visit 4) to the end of treatment (Visit 7) in response to L-NMMA infusion was to be calculated as the change from the pre L-NMMA infusion (S1) to the end of the L-NMMA infusion (S2). A comparison of treatment groups was to be made using an analysis of covariance (ANCOVA) with pooled centre and treatment included as main effects and RPF (in response to L NMMA infusion) at baseline as a covariate. The treatment group difference, adjusted for the other factors in the model, was to be presented with a corresponding 95% confidence interval (CI) and a test of statistical significance. The model was also to be used to provide analysis results for the within treatment group changes.

Intervention(s) in this Clinical Trial

• Drug: Telmisartan
• Drug: Ramipril

Primary Measures

• Change in RPF from baseline (Visit 4) to the end of treatment (Visit 7) in response to L-NMMA infusion

Secondary Measures

• Change from baseline in Renal function parameters before and in response to L-NMMA and L-arginine hydrochloride infusion; angiotensin II, aldosterone, ADMA, L-arginine urinary excretion parameters blood pressure, augmentation index

Inclusion Criteria:

• Hypertensive patients aged 30-80 years with type 2 diabetes, normo- or microalbuminuria, GFR > 80 mL/min (Cockroft-Gault)

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 30 Years

Maximum Age for this Clinical Trial: 80 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: Boehringer Ingelheim Pharmaceuticals

Overall Clinical Trial Officials and Contacts

Boehringer Ingelheim Study Coordinator Study Chair B.I. Pharma GmbH & Co. KG  

Information obtained from ClinicalTrials.gov on October 07, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00240422

Study ID Number: 502.398

ClinicalTrials.gov Identifier: NCT00240422

Health Authority: Germany: Bundesagentur für Arzneimittel und Medizinprodukte